BCL2 and non-small cell lung carcinoma: Gefitinib in combination with AT-101 (a pan-Bcl-2 inhibitor) significantly inhibits cell proliferation, as well as promotes apoptosis of NSCLC cells involving blocking of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-xl (Bcl-xl), and myeloid cell leukemia-1 (Mcl-1) and downregulating of EGFR signaling [37, 38].